Biophytis SA (BPTS): Price and Financial Metrics


Biophytis SA (BPTS): $1.27

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BPTS Stock Price Chart Interactive Chart >

Price chart for BPTS

BPTS Price/Volume Stats

Current price $1.27 52-week high $13.17
Prev. close $1.27 52-week low $1.00
Day low $1.27 Volume 1,700
Day high $1.27 Avg. volume 32,610
50-day MA $2.00 Dividend yield N/A
200-day MA $6.32 Market Cap 17.34M

Biophytis SA (BPTS) Company Bio


Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.


BPTS Latest News Stream


Event/Time News Detail
Loading, please wait...

BPTS Latest Social Stream


Loading social stream, please wait...

View Full BPTS Social Stream

Latest BPTS News From Around the Web

Below are the latest news stories about Biophytis SA that investors may wish to consider to help them evaluate BPTS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

With a weekend of rest under our belts, we're ready to jump back into investing with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | February 7, 2022

Analysts Are Bullish on Top Healthcare Stocks: BioCardia (BCDA), Biophytis (BPTS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCardia (BCDA – Research Report) and Biophytis (BPTS – Research Report) with bullish sentiments. BioCardia (BCDA) In a report released today, Emanuela Branchetti from H.C. Wainwright reiterated a Buy rating on BioCardia, with a price target of $9.00. The company's shares closed last Thursday at $2.09. According to TipRanks.com, Branchetti is ranked #6696 out of 7784 analysts. Currently, the analyst consensus on BioCardia is a Moderate Buy with an average price target of $6.50, which is a 231.6% upside from current levels.

Howard Kim on TipRanks | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | February 3, 2022

BioCardia, Biophytis top healthcare gainers; Kiromic, Mainz Biomed among losers

BioCardia BCDA +32%. Biophytis BPTS +17%. Kiromic BioPharma KRBP -17%. Mainz Biomed (MYNZ) -9%.

Seeking Alpha | February 3, 2022

Biophytis to treat severe COVID-19 patients with Sarconeos in Brazil under EAP

Biophytis (BPTS) soars 21.5% premarket after receiving approval from the ANVISA (Brazilian health authority) for its Expanded Access Program ((EAP)) to treat hospitalized patients

Seeking Alpha | February 3, 2022

Read More 'BPTS' Stories Here

BPTS Price Returns

1-mo -16.72%
3-mo N/A
6-mo -79.19%
1-year -88.71%
3-year N/A
5-year N/A
YTD -76.22%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3206 seconds.